摘要
目的:检测膜联蛋白A2(annexinA2,ANXA2)在输卵管癌组织中的表达情况,并探讨膜联蛋白A2的表达与输卵管癌患者临床病理参数的关系及其预后的相关性。方法:采用免疫组化SP法检测62例输卵管癌组织和25例正常输卵管组织中ANXA2的表达情况,分析其与输卵管癌患者临床病理参数及疾病预后的关系。结果:ANXA2主要定位于细胞膜,亦在细胞质着色,ANXA2在输卵管癌中的高阳性表达率为50%,明显低于正常输卵管组织(96%),P<0.01;ANXA2的高阳性表达率随着输卵管癌分化程度降低而降低(P<0.05);生存曲线分析显示ANXA2阴性表达的输卵管癌患者总体生存率缩短(P<0.05)。结论:ANXA2在输卵管癌组织中表达降低,且与输卵管癌不良预后有关,可用于临床监测输卵管癌患者病情变化。
Objective: To detect the expression of annexin A2( ANXA2) in fallopian tube carcinoma and to further investigate the relationship between annexin A2 and clinicopathological parameters of fallopian tube carcinoma and its prognosis. Methods: The expression of ANXA2 in 62 cases of fallopian tube carcinoma and 25 cases of normal fallopian tube tissues were measured by immunohistochemistry. The relationship between the expression of ANXA2 and clinicopathological parameters and prognosis of patients with fallopian tube cancer were also analyzed. Results: ANXA2 was mainly expressed in the cell membrane,also stained in cytoplasm. The high positive expression rate of ANXA2 in fallopian tube carcinoma was 50%,which was significantly lower than that of normal fallopian tube tissue( 96%),P< 0. 01. With the degree of differentiation decreased,the high positive expression rate of ANXA2 was also decreased( P < 0. 05). The analysis survival curve showed that the overall survival rate of patients with fallopian tube carcinoma with negative ANXA2 expression was shortened( P < 0. 05). Conclusion: ANXA2 expression is decreased in fallopian tube carcinoma and is associated with poor prognosis of fallopian tube carcinoma. It can be used for clinical monitoring of patients with fallopian tube carcinoma.
引文
[1] Semrad N,Watring W,Fu YS,et al.Fallopian tube adenocarcinoma:Common extraperitoneal recurrence[J].Gynecol Oncol,1986,24(2):230-235.
[2] Horng HC,Teng SW,Huang BS,et al.Primary fallopian tube cancer:Domestic data and up-to-date review[J].Taiwan J Obstet Gynecol,2014,53(3):287-292.
[3] Rosenblatt KA,Weiss NS,Schwartz SM.Incidence of malignant fallopian tube tumors[J].Gynecol Oncol,1989,35(2):236-239.
[4] Lau HY,Chen YJ,Yen MS,et al.Primary fallopian tube carcinoma:A clinicopathologic analysis and literature review[J].J Chin Med Assoc,2013,76(10):583-587.
[5] Riska A,Leminen A.Updating on primary fallopian tube carcinoma[J].Acta Obstet Gynecol Scand,2007,86(12):1419-1426.
[6] Huebner K,Cannizzaro LA,Frey AZ,et al.Chromosomal localization of the human genes for lipocortin I and lipocortin II[J].Oncogene Res,1988,2(4):299-310.
[7] Waisman DM.Annexin II tetramer:Structure and function[J].Mol Cell Biochem,1995(149-150):301-322.
[8] Leal MF,Calcagno DQ,Chung J,et al.Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients[J].Clin Exp Med,2015,15(3):415-420.
[9] Yan X,Zhang D,Wu W,et al.Mesenchymal stem cells promote hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a[J].Cancer Res,2017,77(23):6704-6716.
[10] Jaffee E,Zheng L,Abd El-Aleem SA.Assessment of the cellular localisation of the annexin A2/S100A10 complex in human placenta[J].Cell Adh Migr,2018,49(5):531-543.
[11] Yang SF,Hsu HL,Chao TK,et al.Annexin A2 in renal cell carcinoma:expression,function,and prognostic significance[J].Urol Oncol,2015,33(1):22.e11-22.e21.
[12] Jin L,Shen Q,Ding S,et al.Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy[J].Gynecol Oncol,2012,126(1):140-146.
[13] Deng L,Gao Y,Li X,et al.Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma[J].J Exp Clin Cancer Res,2015(34):96.
[14] Zhuang H,Tan M,Liu J,et al.Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells[J].Mol Cancer,2014(13):243.
[15] Madureira PA,Surette AP,Phipps KD,et al.The role of the annexin A2 heterotetramer in vascular fibrinolysis[J].Blood,2011,118(18):4789-4797.
[16] Ling Q,Jacovina AT,Deora A,et al.Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo[J].J Clin Invest,2004,113(1):38-48.
[17] Kim J,Hajjar KA.Annexin II:A plasminogen-plasminogen activator co-receptor[J].Front Biosci,2002(7):341-348.
[18] Feng X,Liu H,Zhang Z,et al.Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells[J].J Exp Clin Cancer Res,2017,36(1):123.
[19] Foley K,Muth S.Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2[J].Cancer,2017,11(5-6):514-523.
[20] GAO YP,DENG L,WANG HM,et al.The expression and clinical significance of annexin A2 in endometrial carcinoma[J].Modern Oncology,2016,24(10):1608-1612.[高一平,邓璐,王慧敏,等.膜联蛋白A2在子宫内膜癌组织中的表达及临床意义[J].现代肿瘤医学,2016,24(10):1608-1612.]
[21] Liu JW,Shen JJ,Tanzillo-Swarts A,et al.Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration[J].Oncogene,2003,22(10):1475-1485.
[22] Rodrigo JP,Lequerica-Fernandez P,Rosado P,et al.Clinical significance of annexin A2 downregulation in oral squamous cell carcinoma[J].Head Neck,2011,33(12):1708-1714.
[23] Mai J,Waisman DM,Sloane BF.Cell surface complex of cathepsin B/annexin II tetramer in malignant progression[J].Biochim Biophys Acta,2000,1477(1-2):215-230.
[24] Zhuang H,Tan M,Liu J,et al.The expression of annexin II and Lewis y antigen in ovarian epithelial tumors and the correlation between them[J].Tumour Biol,2015,36(4):2343-2349.
[25] JIN S,GAO YP,LI X,et al.The expression and significance of CD47 in fallopian tube carcinoma[J].Modern Oncology,2018,26(08):1251-1255.[金山,高一平,李潇,等.CD47在输卵管癌中的表达及临床意义[J].现代肿瘤医学,2018,26(08):1251-1255.]
